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The DNA topoisomerase enzymes I and II are recognized as
important targets for cytotoxic drugs. The anthracyclines and
epidophyllotoxins are widely used topoisomerase II inhibitors
whereas the camptothecins have been developed more recently as
pure inhibitors of topoisomerase I. Unlike other agents in clinical
use, DACA (N-[2-(dimethylamino)ethyl] acridine-4-carboxamide
dihydrochloride), also known as XR5000, is a novel inhibitor of
both topoisomerase I and II.
DACA is one of a series of tri-cyclic carboxamide cytotoxic
agents that have been developed by the Cancer Research
Laboratory in Auckland, New Zealand (Atwell et al, 1987). In
addition to interacting with both topoisomerase I and topoiso-
merase II, DACA has a number of features indicating that it may
be clinically important. First, DACA is able to circumvent several
types of drug resistance. Secondly, DACA is highly active against
certain solid tumour models in vitro and in vivo. Thirdly, DACA
appears to cross the blood–brain barrier in animals. Finally,
DACA has linear pharmacokinetics in preclinical models, is water
soluble, easily formulated and chemically stable.
The structure of DACA is shown in Figure 1. Its formula is
C18H19N3O.2HCl and molecular weight is 366.29. DACA binds to
DNA by intercalation and stimulates the formation of cleavable
complexes between DNA and topoisomerase I and II. It is
distinguishable from amsacrine, another acridine derivative, by its
action on topoisomerase I and by the DNA sequence selectivity of
cleavage in the presence of topoisomerase II (Schneider et al,
1988).
The activity of DACA against both topoisomerase I and II also
distinguishes it from other topoisomerase inhibitors in clinical use.
Moreover, DACA maintains activity against a multi-drug resistant
subline of the P388 leukaemia expressing the P-glycoprotein
(Baguley et al, 1990). Similarly, sublines of the Jurkat human
leukaemia cell line, which have reduced amounts of topoiso-
merase II, are highly resistant to etoposide and doxorubicin, but
retain sensitivity to DACA (Finlay et al, 1993). The pattern of
activity of DACA in vitro against a variety of human and mouse
cell lines, including primary human melanoma cultures derived
from fresh surgical melanoma specimens, is distinct from that of
amsacrine and etoposide (Marshall et al, 1992; Finlay et al, 1993)
with IC50 values between 0.09 mM and 3.4 mM (Finlay et al, 1993).
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Summary DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA
was given as a 3-h intravenous infusion on 3 successive days, repeated every 3 weeks. A total of 41 patients were treated at 11 dose levels
between 9 mg m–2 d–1 and the maximum tolerated dose of 800 mg m–2 day–1 . The commonest, and dose-limiting, toxicity was pain in the
infusion arm. One patient given DACA through a central venous catheter experienced chest pain with transient electrocardiogram changes,
but no evidence of myocardial infarction. At the highest dose levels, several patients also experienced flushing, pain and paraesthesia around
the mouth, eyes and nose and a feeling of agitation. Other side-effects, such as nausea and vomiting, myelosuppression, stomatitis and
alopecia, were uncommon. There was one minor response but no objective responses. DACA pharmacokinetics were linear and did not differ
between days 1 and 3. The pattern of toxicity seen with DACA is unusual and appears related to the mode of delivery. It is possible that higher
doses of DACA could be administered using a different schedule of administration.
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DACA has only moderate activity in vivo against P388
leukaemia and L1210 leukaemia. It is, however, highly active
against Lewis lung carcinoma in mice (Atwell et al, 1987; Finlay
and Baguley, 1989), the murine 16/C tumour and Colon 11 A and
Colon 38 tumours (Baguley et al, 1995). In preclinical pharma-
cology studies the unbound fraction of DACA in mouse plasma
was 15.8%. DACA was extensively metabolized and demon-
strated biphasic elimination, predominantly in the faeces (Evans
et al, 1992; Paxton et al, 1992, 1993a, 1993b). Tissue levels of
DACA were substantially higher in brain, liver, kidney and heart,
than in plasma.
The principle objective of this study was to determine the
maximum tolerated dose (MTD) of DACA given intravenously
(i.v.) over 3 successive days repeated every 3 weeks in patients
with solid tumours. The other aims were to determine the safety
profile of DACA, study the pharmacokinetics of DACA and
describe any evidence of anti-tumour activity.
MATERIALS AND METHODS
This study was conducted under the auspices of the Cancer
Research Campaign Phase I/II Clinical Trials Committee at
Addenbrooke’s Hospital (Cambridge), the Beatson Oncology
Centre (Glasgow) and the Royal Marsden Hospital (Sutton). The
study protocol and informed consent forms were reviewed and
approved by the Ethics Committee at each hospital; written
informed consent was obtained from each patient prior to study
entry.
Study design
Doses of DACA were calculated as mg salt per m2 of body surface
area. The starting dose was based on murine data. The LD10 dose
in mice for a single i.v. dose was 58  mg/kg and for five consecu-
tive daily i.v. doses was approximately 30 mg kg–1 per day. The
starting dose was 9 mg m–2 given daily on 3 successive days, 1/10
of the mouse LD10. Dose escalation was according to a modified
Fibonacci scheme.
Two patients were entered at the first dose level and at least
three patients at further dose levels. If one of these patients experi-
enced a dose-limiting toxicity (DLT), the number of patients
treated at that dose level was increased to six. There was an
interval of at least 1 week between the entry of patients at any one
dose level. Entry of patients at the next dose level was delayed
3 weeks in order that toxicity could be assessed prior to escalation.
The MTD was defined as the dose at which DLTs occur in 33%
or more of patients. DLTs were defined as (i) white blood count
nadir of less than 0.5 ´ 109 l–1 or a platelet nadir less than
50 ´ 109 l–1, (ii) failure to recover by day 35 after the previous
treatment to a granulocyte count of 1.5 ´ 109 l–1 or platelet count of
100 ´ 109 l–1, (iii) common toxicity criteria (CTC) grade 3 or grade
4 non-haematological toxicity (except for alopecia or nausea and
vomiting) unless considered unequivocally to be unrelated to
DACA.
Patient population
Prior to study entry all patients had a baseline history and full
physical examination with electrocardiogram (ECG), radiological
and laboratory evaluation.
Inclusion criteria included:
i. histologically confirmed metastatic solid tumour refractory
to conventional therapy, or for which there was no standard
therapy
ii. age ³ 18 years
iii.WHO performance status 0, 1 or 2 and life expectancy of at
least 3 months
iv. adequate haemopoetic reserve, defined as a granulocyte count
³ 2 ´ 109 l–1 and platelet count ³ 100 ´ 109 l–1
v. adequate renal function, defined as serum creatinine
≤ 0.14 mmol l–1
vi.adequate hepatic function, defined as serum bilirubin ≤ 1.5 ´
the upper limit of normal, with transaminases and alkaline
phosphatase ≤ 2 ´ upper limit of normal and normal
prothrombin time.
Major exclusion criteria were:
i. pregnancy, lactating or not taking adequate contraceptive
precautions,
ii. chemotherapy or radiotherapy within the previous 4 weeks (at
least 6 weeks since treatment with nitrosureas or mitomycin C)
iii.major surgery within the previous 14 days; intercurrent or
serious infection within the previous 28 days
iv. life-threatening illness unrelated to cancer.
Whilst on treatment, patients underwent weekly clinical review,
performance status was recorded and blood taken for full blood
count and biochemistry. Other investigations including ECG and
chest X-ray were repeated if clinically indicated. Treatment toxi-
city was assessed using the National Cancer Institute Common
Toxicity Criteria and response evaluated according to WHO
criteria.
Treatment
The concentration of DACA, based on the dihydrochloride salt,
was 44 mg ml–1. However, all DACA doses are based on the
nominal concentration of 50 mg ml–1, which represents the
concentration of the raw material containing 12% water.
DACA was supplied by the Cancer Research Laboratory,
Auckland Medical School, Auckland, New Zealand and formu-
lated at the CRC Formulation Unit at Strathclyde University. The
diluted drug is stable at room temperature for at least 6 months.
DACA was provided to the clinical centres as an aqueous solution,
adjusted to pH 7.1 with sodium hydroxide, in ampoules containing
1.1 ml, 2.2 ml, 5.5 ml at a nominal concentration of 50 mg ml–1.
DACA was further diluted and administered in 500-ml isotonic
saline unless otherwise stated.
The infusion was to run over 3 h, using an infusion pump with
i.v. access via a plastic peripheral venous cannula, on 3 successive
days. Treatment was to be repeated every 21 days, provided the
granulocyte count was ³ 1.5 ´ 109 1–1 and platelets ³ 100 ´ 109 l–1.
Patients who experienced unacceptable toxicity, had progressive
disease, or withdrew their consent, did not receive further DACA.
Pharmacokinetics
Blood samples of approximately 7 ml were taken from an
indwelling venous cannula into a heparinized tube and centrifuged
at 2000 rpm for 5 min. The plasma was separated and frozen at1788 CJ Twelves et al
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–20°C pending assay. On day 1 of the first infusion a total of
18 samples were taken at the following times: 0 (before infusion),
30min, 1h, 1h 30min, 2h, 2h 30min, 3h (end of infusion),
3h 10min, 3h 20min, 3h 45min, 4h, 4h 30min, 5h, 6h, 8h,
12h, 18h and 24h. On day 3 this schedule was repeated with
additional samples at 48h, 72h, 96h and 120h. Where the infu-
sion time was prolonged beyond 3h, an end of infusion sample
was collected.
DACA concentrations were determined by high-performance
liquid chromatography (HPLC). In brief, 200ml of plasma were
added to 1ml of acetonitrile and internal standard, mixed and
centrifuged at 10000rpm for 10min at 4°C. The supernatant was
dried, the residue suspended in 200ml of mobile phase and
centrifuged for 3min at 10000rpm then the supernatant injected
onto the HPLC. The system used a Brownlee RP18 precolumn and
Phenomenex Primasphere 5mm C18, 250mm analytical column.
The mobile phase was 28% acetonitrile and 10mMTEAP
(aqueous triethylamine solution adjusted to pH 2 with orthophos-
phoric acid; 1Mstock diluted 1:100). The flow rate was 1ml per
min and fluorescence detection was used (excitation 360nm,
emission > 450nm). The assay was linear between 0.01mMand
10mMand the coefficient of variation was < 10% for all quality
control samples. All pharmacokinetic data are expressed in terms
of the dihydrochloride salt.
Both compartmental and non-compartmental pharmacokinetic
parameters were calculated using WinNonLin (Scientific
Consulting Inc., North Carolina, USA). The area under the
concentration-time curve (AUC)0 ®∞ of DACA was calculated
using the linear trapezoidal rule with extrapolation to infinity.
Comparable AUC0 ®∞ from both compartmental and model
independent (non-compartmental) analysis indicated that the
choice of model was correct. The selection of best fit was made
by comparing residual plots, the Akaike Information Criteria and
the standard errors (s.e.) of the parameter estimates.
The data were initially modelled with non-compartmental
analysis to give the following parameters: AUC0 ®∞, mean reten-
tion time (MRT), clearance (Cl), elimination half-life (T1/2ß), peak
concentration (Cmax), time to reach peak concentration (Tmax) and
volume of distribution at steady state (Vss). The data were
subsequently modelled using both one-compartment and two-
compartment models with uniform weighting.
RESULTS
Patients
Forty-one patients were treated in cohorts of between 3 and 9 at
11 dose levels between 9mg m–2 and 800mg m–2. Their clinical
characteristics are shown in Table 1. Patients were typical of
those included in phase I studies. The commonest tumour types
were lung carcinoma, colorectal carcinoma, renal carcinoma
and soft tissue sarcoma. Most patients had received at least one
non-surgical treatment prior to study entry. The 41 patients
received a total of 70 courses of DACA (median 2, range 1–6),
although 5 did not receive a full course of three infusions.
Maximum tolerated dose
The MTD for DACA given as a 3h i.v. infusion was 800mg m–2 d–1
. At this dose level all patients experienced significant toxicity. The
DLT was pain during the infusion of DACA. This cohort was
expanded to nine patients in order to define better the pattern of
toxicity. In all, at the 800mg m–2 dose level four patients stopped
DACA because of toxicity and a further two experienced unaccept-
able toxicity. Of the nine patients treated at 800mg m–2, one devel-
oped severe chest pain (see below), four had moderate and three
had severe arm pain. Prophylactic administration of dex-
amethasone, nifedipine or analgesics did not prevent the pain. It
still occurred when the infusion volume was increased from 500ml
to 1 litre. Five patients also developed a rash or flushing over the
upper trunk or face. Six patients reported oral/perioral paraesthe-
siae or burning, whilst three experienced either lacrimation or pres-
sure behind the eyes.
Also at the 800mg m–2 dose level, one patient developed throm-
bosis of the right innominate vein confirmed by upper limb venog-
raphy. She had, however, a past history of left innominate vein
thrombosis with residual stenosis that may have predisposed her to
further thrombosis. Grade 3 diarrhoea and grade 3 vomiting were
each experienced by one patient.
Toxicities
Important toxicities considered almost certainly, probably or
possibly related to treatment in each patient at that dose level are
shown in Table 2. There were two deaths following the first cycle
of DACA. A 73-year-old man with metastatic melanoma died at
home 15 days after treatment with DACA 36mg m–2 d–1; post-
mortem examination showed left ventricular hypertrophy. The
second, a 72-year-old male with lung cancer, was not myelosup-
pressed but developed a chest infection and died 10 days after
treatment with 250mg m–2 d–1 DACA. Neither was attributed to
DACA by the investigator.
At dose levels up to and including 600mg m–2 d–1 DACA was
generally well-tolerated although pain at or proximal to the infu-
sion site was seen at all doses. There was, however, considerable
variability in the severity of the arm pain between patients at each
dose level. There were also differences between infusions in the
same patient. Some patients described ‘burning’ at the site of the
Table 1Patient characteristics
No. of patients 41
Male/female 27/14
Median age (range) 55 years (31–73)
Performance status
08
126
27
Prior non-surgical treatment
None 1
Chemotherapy 19a
Radiotherapy 11b
Radiotherapy & chemotherapy 8*
Endocrine or immunotherapy 2
Tumour type
Lung carcinoma 13
Colorectal carcinoma 7
Soft tissue sarcoma 6
Renal carcinoma 5
Ovarian carcinoma 4
Other 6
aTwo also had endocrine/immunotherapy; bThree also had immunotherapy.Phase I study of DACA 1789
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infusion, whilst others reported pain elsewhere in the arm. There
was no redness or swelling at the site of infusion or discolouration
over the infusion vein and no evidence of extravasation. Slowing
or discontinuation of the infusion usually led to rapid resolution of
the pain; it was often possible to re-start DACA at a slower infu-
sion rate and then increase the rate of infusion. At the 800 mg m–2,
however, the arm pain was more consistent and more severe.
Several patients also described a pattern of side-effects that
were unusual but not severe. One patient treated at the 450 mg m–2
dose level, reported feeling sleepy (grade 2); at the 600 mg m–2
dose level another felt drowsy and on another occasion uncoordi-
nated and ‘disembodied’ (grade 1). Paraesthesia (grade 1) around
the mouth was seen in one patient at 450 mg m–2 dose level. At the
600 mg m–2 dose level, another patient reported burning around
the mouth, face, eyes and throat associated with excessive lacrima-
tion (grade 2). At the 800 mg m–2 dose level, several patients
described transient pain or paraesthesia around the mouth, altered
taste, flushing or a sensation of anxiety.
A 36-year-old woman, treated at the 800 mg m–2 dose level
through a central venous catheter, experienced chest pain 30 min
after the infusion started. This was associated with a burning sensa-
tion extending from her neck to her throat and mouth, and paraes-
thesia. Despite glyceryl trinitrite, after the infusion had been
running for 190 min the central chest pain became severe (grade 3)
with heaviness and tingling in her left arm. An ECG showed flat-
tening of the T waves in the chest leads. The symptoms and ECG
changes were suggestive of myocardial ischaemia. After the infu-
sion was stopped and i.v. diamorphine given, the pain and ECG
changes resolved rapidly; there were no changes in cardiac
enzymes. She had no prior history of cardiovascular disease and did
not experience further chest pain, but was not given further DACA.
Clinically significant myelosuppression was rare. There was no
dose-limiting myelosuppression at dose levels up to and including
600 mg m–2 with only one patient (treated at the 350 mg m–2 dose
level) developing grade 1 thrombocytopenia. At the 800 mg m–2
dose level one patient had grade 1 neutropenia; a second patient
experienced transient uncomplicated grade 4 thrombocytopenia
and neutropenia on day 11 of cycle 2. Although this fulfilled the
definition of DLT, it was transient and uncomplicated. It should
also be noted that this patient had previously undergone high-dose
chemotherapy with peripheral stem cell support and may have
been more susceptible to myelosuppression. There were no
episodes of grade 3 or grade 4 infection or fever related to DACA.
Although prophylactic antiemetics were not administered,
nausea and vomiting was generally mild. One patient at the
800 mg m–2 dose level had grade 3 vomiting that led to discontinu-
ation of DACA but resolved following ondansetron. No signifi-
cant changes in urea and electrolytes, calcium or liver
biochemistry tests were observed in relation to DACA.
Pharmacokinetics
Thirty six patients had samples collected after their first infusion
of DACA and 34 had sampling on day 3. The mean number of
samples taken on day 1 and day 3 were 17 and 18 respectively.
Patients who did not receive the full dose of DACA were excluded
from the pharmacokinetic analysis for that day.
Most patients’ data fitted best a two-compartment model, but
day 1 data from five patients fitted a one-compartment model
better. A typical concentration-time curve is shown in Figure 2.
There was a linear relationship between dose and AUC (Figure 3)
on both day 1 (r2 = 0.77, P = 0.0005) and day 3 (r2 = 0.64,
P = 0.006). There was also a linear relationship between dose and
peak plasma concentration on both day 1 (r2 = 0.57, P = 0.007)
Table 2 Worst toxicity experienced by each patient according to dose level
No. of patients Nausea Vomiting Diarrhoea Stomatitis Neuro-cortical Skin Pain-infusion arm Agitation Paraesthesia
Dose level of head/neck/mouth
(mg m–2 day–1)
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
9 2 2 2 2 2 2 2 1 1 2 2
18 3 2 1 3 3 3 3 3 2 1 3 3
36 3 1 2 3 3 3 2 1 3 1 1 1 3 3
60 4 3 1 4 3 1 4 4 4 1 1 2 4 4
100 4 4 4 4 4 4 4 1 1 2 4 4
165 3 3 3 3 3 3 3 1 2 3 3
250 3 3 3 3 3 3 3 1 2 3 3
350 3 1 1 1 3 3 3 3 3 1 2 3 3
450 3 3 3 3 3 3 3 3 3 3
600 5 2 1 2 3 1 1 4 1 4 1 5 4 1 2 3 5 3 1 1
800 9 6 3 6 3 7 1 1 7 1 1 8 1 5 3 1 1 1 5 2 6 1 1 1 2 3 2 2
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and day 3 (r2 = 0.78, P = 0.0001). There were no significant corre-
lations between dose and either clearance or Vss. Table 3 shows a
summary of pharmacokinetic parameters for day 1. Across all dose
levels there were no differences between day 1 and day 3 DACA
plasma clearance (83.9 and 81.11 h–1 respectively), MRT (1.74 and
1.91 h respectively), Tmax (2.91 and 2.69 h respectively), Vss (142.6
and 145.21 respectively) and T1/2b (2.22 and 2.08 h respectively).
The patient who experienced chest pain had a Cmax of
3.15 mg ml–1, similar to that of other patients treated at the 800 mg
m–2 dose level (range 2.31–12.1 mg ml–1). There was no significant
relationship between either Cmax or AUC and severity of arm pain
during infusion of DACA. Interestingly, the only patient with
significant myelosuppression had the highest AUC on day 3 of all
patients in the study (54.2 mg ml–1 h).
Anti-tumour activity
There were no objective responses to DACA according to WHO
criteria. Seven patients treated at doses between 60 and
800 mg m–2 had stable disease with progression-free intervals
between 6 and 20 weeks. These included one patient with breast
cancer and multiple small pulmonary metastases who received
DACA 800  mg m–2. Repeat computerized tomography scans
showed a reduction in the number and size of these lesions, but this
did not satisfy WHO criteria for a partial response.
DISCUSSION
Many of the cytotoxic drugs in clinical use act against one or other
of the DNA topoisomerases I and II. Preclinical data suggest that it
may be worthwhile to combine inhibitors of topoisomerase I and
II. Tan et al (1989) derived separate P388 leukaemia cell lines
resistant to topoisomerase I or II. The topoisomerase I-resistant
variants had reduced topoisomerase I levels but increased levels of
topoisomerase II. Likewise, topoisomerase II levels were reduced
in the topoisomerase II-resistant line but topoisomerase I levels
were elevated. There was a similar pattern in Chinese hamster
ovary cells (Gupta et al, 1988), A549 human lung cancer and
HT29 colon cancer cell lines (Sugimoto et al, 1990). These data
suggest that resistance to inhibitors of one topoisomerase may be
associated with increased sensitivity to inhibitors of the other and
raises the possibility of synergy between topoisomerase I and II
inhibitors. This beneficial effect on cytotoxicity is seen in some
human cell lines (Kano et al, 1992) but not in others (Kaufman
et al, 1991).
In the clinic, attempts to combine topoisomerase I and II
inhibitors have had limited success. Until recently, actinomycin D
was the only single agent with demonstrable activity against topo-
isomerases I and II (Tewey et al, 1984; Trask and Muller, 1988). In
a phase I trial of intoplicine, a 7-H-benzo[e]pyridol[4,3-b]-indole
derivative that also has activity against topoisomerases I and II,
hepatotoxicity was dose-limiting (Abigerges et al, 1996). When
the established inhibitors of topoisomerase I and II irinotecan and
etoposide were combined, diarrhoea and myelosuppression were
severe (Karato et al, 1993). Although the combination was active,
the toxicities were considered unacceptable despite granulocyte
colony-stimulating factor support. As a novel inhibitor of topoiso-
merases I and II, DACA offers a different approach. DACA is
active in several preclinical tumour models and a striking feature is
the ability of DACA to overcome a number of mechanisms of drug
resistance.
In this study, DACA was generally well-tolerated at all but the
highest dose level of 800 mg m–2 given on 3 successive days. The
DLT was pain felt in the arm during infusion. In contrast to most
cytotoxic agents, toxicities such as alopecia, stomatitis, myelosup-
pression and nausea and vomiting were uncommon. The arm pain
occurred at all dose levels, but varied in intensity between patients
at each dose level and also between infusions in the same patients.
In all cases, the pain was reversible and there were no sequelae. At
the highest dose level, flushing, perioral paraesthesia and pain
were also seen.
Table 3 Summary of pharmacokinetic parameters for day 1
Dose (mg m–2) AUC∞ CI (I h–1) MRT (h) Cmax (mg ml–1) Tmax (h)
(mg ml–1 h)
9 0.20 ± 0.03 72.79 ± 2.91 0.98 ± 0.16 0.08 ± 0.007 3.08 ± 0.11
18 0.48 ± 0.23 85.14 ± 54.8 1.82 ± 0.84 0.09 ± 0.018 2.66 ± 0.29
36 0.82 ± 0.39 99.24 ± 46.9 1.93 ± 1.13 0.24 ± 0.076 3.08 ± 0.14
60 1.62 ± 0.69 76.14 ± 30.6 1.23 ± 0.28 0.51 ± 0.229 3.06 ± 0.09
100 2.15 ± 0.46 92.35 ± 27.6 1.64 ± 0.63 0.56 ± 0.106 2.42 ± 0.69
165 3.52 ± 0.51 92.97 ± 37.1 1.05 ± 0.29 0.97 ± 0.176 2.79 ± 0.51
250 6.59 ± 1.04 64.60 ± 3.56 1.23 ± 0.03 2.22 ± 0.328 2.92 ± 0.39
350 7.72 ± 1.03 78.11 ± 10.9 1.64 ± 0.82 2.09 ± 0.115 3.17 ± 0.83
450 8.05 ± 2.12 98.85 ± 15.5 1.38 ± 0.23 2.38 ± 0.74 2.75 ± 0.58
600 16.3 ± 4.15 82.90 ± 24.9 2.78 ± 2.54 3.77 ± 0.48 2.33 ± 0.57
800 21.5 ± 10.7 76.26 ± 34.1 2.43 ± 1.33 4.84 ± 4.09 3.72 ± 1.67
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Figure 3 Relationship between DACA dose and AUCThe pattern of toxicities seen with DACA is unusual and the
mechanism unclear. The arm pain cannot be attributed to throm-
bophlebitis, as it was not limited to the course of the vein, and
there were no visible changes in the skin overlying the vein. In no
case was the pain associated with extravasation and in many
patients the pain extended proximally up the arm. Attempts to
abrogate this pain by the use of prophylactic analgesics and
vasoactive substances were unsuccessful. The pain was often
worst early in the infusion and settled when the infusion rate was
slowed. This probably explains the absence of any relationship
between Cmax and the arm pain. Nevertheless, the pain clearly was
dose-related and determined by the mode of administration. One
explanation for the arm pain would be vasoconstriction, but
DACA appears not to be a potent vasoconstrictor (Xenova,
personal communication). An alternative explanation would be
action on local pain receptors, either directly or by stimulating
release of peptide. This would be compatible with the ‘tachy-
phylaxis’ seen during the infusion and might also explain the
perioral symptoms and flushing. Another possibility is an effect
on plasma-ionized calcium levels.
Clearly in this study peripheral venous administration of DACA
was not tolerable at the highest dose levels. Central venous admin-
istration would have been an alternative, but the only patient who
received DACA by this route experienced chest pain associated
with ECG changes. Although the pain was cardiac in nature, both
the pain and ECG changes resolved rapidly following discontinua-
tion of the infusion and there was no evidence of myocardial
infarction. The mechanism of chest pain is again unclear.
Nevertheless, the administration of DACA through a central
venous catheter at this dose and using the current schedule would
be inappropriate.
The difficulties in administering DACA as a peripheral infusion
may explain the limited evidence of anti-proliferative activity.
There were no objective tumour responses but a woman with
breast cancer treated at the 800 mg m–2 dose level had a reduction
in the number and size of her pulmonary metastases. This did not,
however, satisfy standard criteria for a partial response. This
patient also experienced dose-limiting myelosuppression, but had
previously undergone high-dose chemotherapy and was probably
more susceptible to myelosuppression. Nevertheless, it appears
that using this schedule, a dose of 800 mg m–2 on 3 successive days
may be close to that which has significant anti-proliferative
activity.
In a second phase I trial of DACA conducted in New Zealand
DACA was given as a 3-h infusion on a single day. Arm pain was
again the DLT (B Evans, personal communication). These trials
raise the question of how higher doses of DACA, which may have
useful anti-tumour activity, can be administered. If the toxicities
related to delivery can be overcome, it should be possible safely to
escalate DACA doses further as the pharmacokinetic data have
confirmed that DACA kinetics are linear over the dose range
studied. With no evidence of time dependency in DACA pharma-
cokinetics between day 1 and day 3, it may be possible to admin-
ister DACA over a more prolonged period. This would reduce the
peak levels of DACA to which patients are exposed.
In conclusion, we have demonstrated that the MTD for DACA
given as a 3-hour i.v. infusion on 3 successive days repeated every
3 weeks is 800 mg m–2 day–1. The DLT was arm pain and the MTD
was determined by symptoms related to mode of administration,
which would have made further treatment unacceptable.
Alternative means of delivery should be explored with DACA in
future phase I studies.
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